IART Integra Lifesciences Holdings Corp
- Stocks
- Healthcare
- NASDAQ: IART
Price (delayed)
$13.44
Market cap
$1.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$2.82B
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra
Highlights
The revenue is up by 6% year-on-year
IART's EPS has dropped by 175% year-on-year
Integra Lifesciences Holdings's net income has plunged by 172% YoY
Key stats
What are the main financial stats of IART
Market
Valuations
Earnings
Shares outstanding
77.71M
Market cap
$1.04B
Enterprise value
$2.82B
Price to earnings (P/E)
N/A
Price to book (P/B)
0.68
Price to sales (P/S)
0.63
EV/EBIT
86.16
EV/EBITDA
15.63
EV/Sales
1.74
Revenue
$1.62B
Gross profit
$869.66M
Operating income
$8.95M
Net income
-$28.96M
EBIT
$32.78M
EBITDA
$180.73M
Free cash flow
-$15.5M
Per share
Balance sheet
Liquidity
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
-$0.2
Book value per share
$19.74
Revenue per share
$21.24
TBVPS
$23.02
Total assets
$4.05B
Total liabilities
$2.53B
Debt
$2.02B
Equity
$1.52B
Working capital
$188.8M
Debt to equity
1.32
Current ratio
1.21
Quick ratio
0.57
Net debt/EBITDA
9.85
Margins
Efficiency
Dividend
EBITDA margin
11.1%
Gross margin
53.5%
Net margin
-1.8%
Operating margin
0.6%
Return on assets
-0.7%
Return on equity
-1.9%
Return on invested capital
1.2%
Return on capital employed
1%
Return on sales
2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IART stock price
How has the Integra Lifesciences Holdings stock price performed over time
Intraday
8.65%
1 week
5.74%
1 month
9.54%
1 year
-45.83%
YTD
-40.74%
QTD
9.54%
Financial performance
How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.62B
Gross profit
$869.66M
Operating income
$8.95M
Net income
-$28.96M
Gross margin
53.5%
Net margin
-1.8%
Integra Lifesciences Holdings's net income has plunged by 172% YoY
The net margin has dropped by 169% year-on-year
The operating income has dropped by 89% year-on-year and by 68% since the previous quarter
IART's operating margin has dropped by 88% year-on-year and by 67% since the previous quarter
Price vs fundamentals
How does IART's price correlate with its fundamentals
Growth
What is Integra Lifesciences Holdings's growth rate over time
Valuation
What is Integra Lifesciences Holdings stock price valuation
P/E
N/A
P/B
0.68
P/S
0.63
EV/EBIT
86.16
EV/EBITDA
15.63
EV/Sales
1.74
IART's EPS has dropped by 175% year-on-year
The P/B is 75% lower than the 5-year quarterly average of 2.5 and 48% lower than the last 4 quarters average of 1.2
The equity has declined by 4.6% year-on-year
The price to sales (P/S) is 78% less than the 5-year quarterly average of 2.6 and 47% less than the last 4 quarters average of 1.1
The revenue is up by 6% year-on-year
Efficiency
How efficient is Integra Lifesciences Holdings business performance
Integra Lifesciences Holdings's return on equity has shrunk by 176% YoY
IART's ROA has shrunk by 170% YoY
IART's return on sales has dropped by 69% year-on-year and by 39% since the previous quarter
IART's return on invested capital has dropped by 66% year-on-year and by 33% since the previous quarter
Dividends
What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IART.
Financial health
How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 60% higher than its total liabilities
IART's quick ratio has plunged by 81% YoY and by 3.4% from the previous quarter
The current ratio has dropped by 74% year-on-year but it has grown by 3.4% since the previous quarter
The debt is 32% greater than the equity
The equity has declined by 4.6% year-on-year
Integra Lifesciences Holdings's debt to equity has increased by 3.1% QoQ and by 3.1% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.